Connect Biopharma Holdings Limited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Connect Biopharma Holdings Limited (CNTB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 242.65 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-12
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 87.42K shares, a 64.93% decline year-over-year.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 155.23K shares, a 86.99% decline year-over-year.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 474.77K shares.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 432.79K shares.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 2.35M shares, a 8.87% decline from fiscal 2024.
- Connect Biopharma Holdings Limited share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 2.58M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 87.42K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 242.65K shares 10-Q · filed 2026-08-12 | 717.43K shares derived: sum of 3 quarters · filed 2026-08-12 | 1.15M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 155.23K shares 10-Q · filed 2026-05-12 | 630.01K shares derived: sum of 2 quarters · filed 2026-05-12 | 1.06M shares derived: sum of 3 quarters · filed 2026-05-12 | 1.31M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 474.77K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 907.56K shares derived: sum of 2 quarters · filed 2026-03-31 | 1.16M shares derived: sum of 3 quarters · filed 2026-03-31 | 2.35M shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 432.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 682.08K shares derived: sum of 2 quarters · filed 2025-11-12 | 1.88M shares 10-Q · filed 2025-11-12 | |
| 2025-06-30 | 249.29K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 1.44M shares 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | 1.19M shares 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | 2.58M shares 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |